产品详情 |
Edit |   |
Product Name | Monoclonal Antibody Development |
Description | The monoclonal antibody development is divided into Phases, with the option of halting the hybridoma production prior to the beginning of the next Phase. The development Phases are as follows: Phase 1: ImmunizationImmunization of mice (Balb/c) with antigen to stimulate antibody production. You may choose to follow our standard immunization protocol, or work with our staff to use your own protocol. Periodic serum samples are analyzed for antibody production using ELISA. If desired, clients can request serum samples for additional characterization. ELISA will be used to determine the highest titer mice to be used for cell fusion. Phase 2: FusionFusion of spleen cells with myeloma cell line. The fused cells are then placed in several 96-well culture plates. Viable colonies appear as early as 3-5 days after fusion and are kept healthy with a fresh supply of nutrient media as necessary. Phase 3: ScreeningWhen hybridoma colonies are large enough to screen, screening of all wells containing fusion products is done with ELISA assay. All positive wells will be expanded and frozen for parental hybridomas. The number of positives depends on the nature of the antigen, and can range from a few hybridomas to a dozen or more. Additional hybrids can be frozen for further studies. Phase 4: Pilot ProductionAfter positive hybridomas are selected for further development, they will be cloned using the limiting dilution method and screened by ELISA. Clones with the desired specificity will be expanded, or harvested for ascites production. Arista Biologicals will make every effort to provide the customer with this custom service in the shortest possible time. A period of three to nine months will normally be required for completion of the project. Delays may be incurred if the antigen is poorly immunogenic or produces unstable clones.The success of the project is dependent upon the material used, supplied by either the customer or by our supplier. Arista Biologicals does not guarantee that the monoclonal antibodies produced will work in the client's own application. The client is responsible for determining the utility of these antibodies in their specific applications. The customer must do further testing to ensure applicability.All clones, cell lines, antibodies and other materials which are the products of this project shall become the exclusive property of the client at the conclusion of the project. Full confidentiality is guaranteed. |
Size | n/a |
Concentration | n/a |
Applications | n/a |
Other Names | n/a |
Gene, Accession, CAS # | n/a |
Catalog # | n/a |
Price | |
Order / More Info | Monoclonal Antibody Development from ARISTA BIOLOGICALS INC. |
Product Specific References | n/a |
产品资料 |
|
|